2024-512821-10-00招募中2 期
ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group4 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年4月26日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 4
- 主要终点
- Main study: Histo-pathological response to pre-operative carboplatin/olaparib compared with pre-operative TAC-based chemotherapy when measured by centrally assessed RCB (RCB-0/I versus RCB-II/III).
研究概览
简要总结
To compare the efficacy of 6 cycles of pre-operative carboplatin/olaparib with 6 cycles of pre-operative taxane/anthracycline-based chemotherapy (TAC) in tumors exhibiting positive homologous recombination deficiency (HRD) status when measured by centrally assessed RCB at the time of surgery.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Main study:
- •Signed informed consent prior to any study specific assessments and procedures
- •Main study:
- •Willingness to undergo adequate lymph node procedures (e.g., sentinel/ axillary lymph node dissection) acc. to institutional standards
- •Main study:
- •Patients must have normal organ and bone marrow function measured within 28 days prior to randomization as defined below: • Haemoglobin (Hb) ≥10.0 g/dL • Absolute neutrophil count (ANC) ≥1.5 x 109/L • Absence of known Myelodysplastic Syndrome (MDS)/ Acute Myeloid Leukaemia (AML) and no features suggestive of MDS/ AML on *peripheral blood smear (*For patients randomized according to protocol version 2.0, peripheral blood smear only has to be performed if haematology assessment during screening shows abnormalities that require further clarification) • White blood cell (WBC) count ≥ 3.0 x 109/L • Platelet count ≥100 x 109/L • Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) • AST (SGOT)/ ALT (SGPT) ≤2.5 x institutional ULN • Serum creatinine ≤1.5 x institutional ULN or creatinine clearance using the Cockcroft-Gault equation ≥51 mL/min
- •Main study:
- •ECOG performance status 0-1
- •Signed informed consent prior to any substudy specific assessments and procedures. Consent to substudy is optional.
- •Completed at least 4 cycles neoadjuvant chemotherapy with TAC or neoadjuvant olaparib and carboplatin in the course of the ABCSG 45 main study.
- •Completed locoregional therapy (i.e. adequate breast and axilla surgery with or without adjuvant radiotherapy). Patients must have recovered from any effects of any major surgery.
- •Treatment with adjuvant olaparib starts ideally within 8 weeks after last treatment (surgery, or radiotherapy, whichever is last), but in no case longer than 12 weeks.
- •Negative pregnancy test (serum or urine) max. 28 days prior to treatment start for women with childbearing potential
- •Women of childbearing potential and male patients must use adequate contraception for the duration of protocol treatment and for 6 months after the last dose of olaparib for women and 3 months after the last dose of olaparib for men. Adequate contraception is defined as one highly effective form (i.e. total abstinence, (fe)male sterilization) OR two effective forms (e.g. non-hormonal intrauterine device (IUD) and condom/occlusive cap with spermicidal foam/gel/film/cream/suppository).
- •Patient is willing and able to comply with the protocol for the duration of the substudy, including undergoing treatment, scheduled visits and examinations.
- •Main study:
- •Negative pregnancy test (serum or urine) max. 28 days prior to randomization for women with childbearing potential: • Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before randomization, as determined by local practice, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation
- •Patients must have adequate organ and bone marrow function measured within 28 days prior to treatment start with no blood transfusions (packed red blood cells and/or platelet transfusions) in the past 28 days prior to testing for organ and bone marrow function
- •ECOG performance status 0-1
- •Main study:
- •Women of childbearing potential and male patients randomized into treatment Arm A or B must use adequate contraception for the duration of protocol treatment and for 6 months after the last dose of (N)IMP for women and 3 months for male patients. Adequate contraception is defined as one highly effective form (i.e. total abstinence, (fe)male sterilization) OR two effective forms (e.g. non-hormonal intrauterine device (IUD) and condom/occlusive cap with spermicidal foam/gel/film/cream/suppository)
- •Main study:
- •Patient is willing and able to comply with the protocol for the duration of the study, incl. undergoing treatment, scheduled visits and examinations
- •Main study:
- •Patients must be ≥ 18 years of age
- •Main study:
- •Pre-menopausal (incl. peri-menopausal) and postmenopausal women and men with core-biopsied, early primary triple-negative (acc. to local standards) invasive breast cancer
- •Main study:
- •Positive HRD status (centrally assessed) in core-biopsy sample of the breast
- •Main study:
- •Absence of distant metastasis (M0) as assessed acc. to institutional standards within 90 days prior to randomization
- •Main study:
- •Unilateral early invasive TNBC patients.
排除标准
- •Main study:
- •Involvement in the planning and/or conduct of the study (applies to both AstraZeneca/ABCSG staff and/or staff at the study site)
- •Main study:
- •Patients with known active hepatic disease (i.e. Hepatitis B or C)
- •Main study:
- •Patients with a known hypersensitivity to olaparib, platins, taxanes, anthracyclines, or cyclophosphamide
- •Main study:
- •Previous randomization in the present study
- •Main study:
- •Patients with uncontrolled seizures
- •Main study:
- •Previous allogeneic bone marrow transplant
- •Main study:
- •Known ≥ grade 2 peripheral neuropathy
- •Main study:
- •Participation in another clinical study with an investigational product during the last 6 months (i.e. 183 days) prior to randomization
- •Main study:
- •Any previous treatment with a PARP inhibitor, including olaparib
- •Main study:
- •Prior ipsilateral invasive breast cancer and/or ipsilateral Ductal Carcinoma in Situ (DCIS) and/or prior chemotherapy for any breast cancer • Patients with contralateral invasive breast cancer and/or contralateral DCIS diagnosed ≥5 years prior to randomization if curatively treated without chemotherapy are eligible
- •Main study:
- •Bilateral invasive breast cancer
- •Main study:
- •Resting ECG with QTc >470 msec and/ or family history of long QT syndrome • However, ECG measurement can be repeated within 24 hours and patient is ineligible if none of these repeated measurements demonstrate QTc ≤470 msec
- •Main study:
- •Patients with second primary malignancy are ineligible except for the following: • Adequately treated non-metastatic, non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, stage 1 grade 1 endometrial carcinoma or • Other curatively treated malignancies diagnosed ≥5 years prior to randomization with no evidence of disease for at least 5 years
- •Main study:
- •Other severe acute and/or chronic medical and/or psychiatric condition and/or laboratory abnormality that would impart, in the judgment of the Investigator, risk associated with study participation or (N)IMP administration, or which, in the judgment of the Investigator, would make the patient inappropriate for participation in this study
- •Main study:
- •Concomitant use of known strong or moderate Cytochrome P450 3A4 (CYP3A4) inducers. For further details refer to Appendix B
- •Exposure to olaparib within 30 days prior to treatment start.
- •Known sensitivity or intolerance to olaparib
- •Adjuvant radiotherapy within 2 weeks prior to treatment start
- •Patients receiving or scheduled to receive adjuvant chemotherapy (e.g. capecitabine).
- •Concomitant use of known strong or moderate Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers.
- •Persistent toxicities (≥ CTCAE grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE grade 2 peripheral neuropathy.
- •Main study:
- •Echocardiography (ECHO) and/or multigated acquisition (MUGA) scan with <50% Left Ventricular Ejection Fraction (LVEF)
- •Main study:
- •Whole blood transfusions within 120 days prior to randomization
- •Main study:
- •Major surgery within 14 days prior to randomization and/or patients with insufficient recovery from any major surgery per physician's assessment at the time of randomization
- •Main study:
- •Any medical condition rendering the patient unfit for pre-operative chemotherapy with TAC or carboplatin/olaparib
- •Main study:
- •Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the (N)IMP
- •Main study:
- •Pregnant or breast feeding women
- •Main study:
- •Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) or patients who are receiving antiretroviral therapy
结局指标
主要结局
Main study: Histo-pathological response to pre-operative carboplatin/olaparib compared with pre-operative TAC-based chemotherapy when measured by centrally assessed RCB (RCB-0/I versus RCB-II/III).
Main study: Histo-pathological response to pre-operative carboplatin/olaparib compared with pre-operative TAC-based chemotherapy when measured by centrally assessed RCB (RCB-0/I versus RCB-II/III).
Substudy: Incidence, nature and severity of adverse events (AEs) graded according to NCI CTCAE, most current version.
Substudy: Incidence, nature and severity of adverse events (AEs) graded according to NCI CTCAE, most current version.
次要结局
- Main study: Occurrence of pCR at the time of surgery.
- Main study: Quality of Life and sexual health scores and changes from baseline as measured using EORTC QLQ-C30, EORTC QLQ-BR45 and EORTC SHQ-C22.
研究者
Trial Office
Scientific
Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group
研究点 (4)
Loading locations...
相似试验
招募中
3 期
Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial2024-516898-72-00Stichting Amsterdam UMC5
招募中
2 期
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monotherapy as first treatment in patients with advanced ALK-positive lung cancer.2023-510387-13-00Intergroupe Francophone De Cancerologie Thoracique110
招募中
3 期
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431)2023-506783-14-00Eli Lilly & Co.42
招募中
3 期
Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC2023-505615-21-00Merck Sharp & Dohme LLC445
招募中
3 期
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BHemophiliaNCT07285460Sanofi85